Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price dropped 6.3% during trading on Tuesday . The company traded as low as $14.12 and last traded at $13.80. Approximately 1,322,340 shares traded hands during trading, a decline of 17% from the average daily volume of 1,601,629 shares. The stock had previously closed at $14.73.
Ginkgo Bioworks Stock Performance
The firm has a market cap of $623.93 million, a P/E ratio of -0.83 and a beta of 1.16. The stock has a 50-day simple moving average of $11.48.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of DNA. Bank of America Corp DE raised its holdings in shares of Ginkgo Bioworks by 780.6% in the 4th quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after purchasing an additional 3,336,964 shares in the last quarter. Erste Asset Management GmbH raised its stake in Ginkgo Bioworks by 47.9% in the fourth quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after buying an additional 239,332 shares in the last quarter. Forbes J M & Co. LLP lifted its holdings in Ginkgo Bioworks by 461.4% during the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after buying an additional 576,732 shares during the period. Millennium Management LLC boosted its position in Ginkgo Bioworks by 357.4% during the 4th quarter. Millennium Management LLC now owns 670,065 shares of the company's stock valued at $6,580,000 after acquiring an additional 523,571 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Ginkgo Bioworks by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 437,025 shares of the company's stock valued at $4,294,000 after acquiring an additional 20,394 shares during the period. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
